CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Seres Therapeutics Inc - MCRB CFD

0.75
1.32%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Seres Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.76
Open* 0.76
1-Year Change* -86%
Day's Range* 0.74 - 0.77
52 wk Range 0.91-6.87
Average Volume (10 days) 9.42M
Average Volume (3 months) 109.39M
Market Cap 158.99M
P/E Ratio -100.00K
Shares Outstanding 129.26M
Revenue 127.24M
EPS -1.13
Dividend (Yield %) N/A
Beta 2.31
Next Earnings Date Mar 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 0.76 0.03 4.11% 0.73 0.77 0.73
Mar 26, 2024 0.73 -0.05 -6.41% 0.78 0.78 0.73
Mar 25, 2024 0.77 0.01 1.32% 0.76 0.79 0.75
Mar 22, 2024 0.75 -0.03 -3.85% 0.78 0.78 0.74
Mar 21, 2024 0.77 -0.04 -4.94% 0.81 0.81 0.75
Mar 20, 2024 0.81 0.03 3.85% 0.78 0.81 0.75
Mar 19, 2024 0.79 0.05 6.76% 0.74 0.83 0.74
Mar 18, 2024 0.74 -0.03 -3.90% 0.77 0.77 0.73
Mar 15, 2024 0.76 0.02 2.70% 0.74 0.77 0.71
Mar 14, 2024 0.74 -0.03 -3.90% 0.77 0.80 0.74
Mar 13, 2024 0.76 -0.01 -1.30% 0.77 0.80 0.74
Mar 12, 2024 0.75 -0.08 -9.64% 0.83 0.83 0.73
Mar 11, 2024 0.84 -0.12 -12.50% 0.96 0.96 0.83
Mar 8, 2024 0.95 -0.01 -1.04% 0.96 1.00 0.94
Mar 7, 2024 0.96 -0.02 -2.04% 0.98 0.99 0.95
Mar 6, 2024 0.99 -0.03 -2.94% 1.02 1.03 0.95
Mar 5, 2024 1.04 0.02 1.96% 1.02 1.07 1.00
Mar 4, 2024 1.12 -0.09 -7.44% 1.21 1.21 1.11
Mar 1, 2024 1.20 0.06 5.26% 1.14 1.21 1.11
Feb 29, 2024 1.12 -0.04 -3.45% 1.16 1.20 1.12

Seres Therapeutics Inc Events

Time (UTC) Country Event
Tuesday, May 7, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Seres Therapeutics Inc Earnings Release
Q1 2024 Seres Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Friday, June 21, 2024

Time (UTC)

12:00

Country

US

Event

Seres Therapeutics Inc Annual Shareholders Meeting
Seres Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 7.128 144.927 33.215 34.505 28.267
Revenue 7.128 144.927 33.215 34.505 28.267
Total Operating Expense 253.618 209.42 121.345 106.381 128.551
Selling/General/Admin. Expenses, Total 85.796 69.261 30.775 24.748 32.596
Research & Development 166.818 141.891 90.57 80.141 95.955
Operating Income -246.49 -64.493 -88.13 -71.876 -100.284
Interest Income (Expense), Net Non-Operating -2.962 -0.04 -1.978 0.531 1.172
Net Income Before Taxes -250.157 -65.578 -89.127 -70.279 -98.942
Net Income After Taxes -250.157 -65.578 -89.127 -70.279 -98.942
Net Income Before Extra. Items -250.157 -65.578 -89.127 -70.279 -98.942
Net Income -250.157 -65.578 -89.127 -70.279 -98.942
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -250.157 -65.578 -89.127 -70.279 -98.942
Income Available to Common Incl. Extra. Items -250.157 -65.578 -89.127 -70.279 -98.942
Diluted Net Income -250.157 -65.578 -89.127 -70.279 -98.942
Diluted Weighted Average Shares 108.077 91.7029 79.7892 56.6492 40.7435
Diluted EPS Excluding Extraordinary Items -2.31462 -0.71511 -1.11703 -1.2406 -2.42841
Diluted Normalized EPS -2.31462 -0.71511 -1.11703 -1.21426 -2.42841
Other, Net -0.705 -1.045 0.981 1.066 0.17
Total Extraordinary Items 0
Dividends per Share - Common Stock Primary Issue
Unusual Expense (Income) 0 0 1.492
Other Operating Expenses, Total 1.004 -1.732
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 126.473 -0.522 0.975 3.444 1.216
Revenue 126.473 -0.522 0.975 3.444 1.216
Total Operating Expense 76.949 70.046 69.282 62.551 64.541
Selling/General/Admin. Expenses, Total 28.051 22.47 22.404 18.384 20.335
Research & Development 46.792 43.969 46.22 43.116 43.935
Operating Income 49.524 -70.568 -68.307 -59.107 -63.325
Interest Income (Expense), Net Non-Operating -1.461 -0.916 -0.466 -0.862 -1.106
Other, Net -1.511 0.31 -0.023 -0.033 -0.304
Net Income Before Taxes 46.552 -71.174 -68.796 -60.002 -64.735
Net Income After Taxes 46.552 -71.174 -68.796 -60.002 -64.735
Net Income Before Extra. Items 46.552 -71.174 -68.796 -60.002 -64.735
Net Income 46.552 -71.174 -68.796 -60.002 -64.735
Income Available to Common Excl. Extra. Items 46.552 -71.174 -68.796 -60.002 -64.735
Income Available to Common Incl. Extra. Items 46.552 -71.174 -68.796 -60.002 -64.735
Diluted Net Income 46.552 -71.174 -68.796 -60.002 -64.735
Diluted Weighted Average Shares 129.845 125.863 125.166 122.527 92.2554
Diluted EPS Excluding Extraordinary Items 0.35852 -0.56549 -0.54964 -0.4897 -0.70169
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.35852 -0.56549 -0.54964 -0.4897 -0.70169
Other Operating Expenses, Total 2.106 3.607 0.658 1.051 0.271
Unusual Expense (Income)
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 194.764 303.628 268.777 100.189 92.665
Cash and Short Term Investments 181.341 290.706 253.616 94.816 85.82
Cash & Equivalents 163.03 180.002 116.049 65.126 85.82
Short Term Investments 18.311 110.704 137.567 29.69 0
Prepaid Expenses 13.423 12.922 5.774 3.588 6.845
Total Assets 348.784 354.859 342.94 132.44 120.472
Property/Plant/Equipment, Total - Net 133.969 36.146 22.938 30.851 26.294
Property/Plant/Equipment, Total - Gross 179.009 76.414 57.258 58.593 46.595
Accumulated Depreciation, Total -45.04 -40.268 -34.32 -27.742 -20.301
Long Term Investments 0 0.495 49.825
Other Long Term Assets, Total 20.051 14.59 1.4 1.4 1.513
Total Current Liabilities 85.596 82.258 46.415 45.993 42.041
Accounts Payable 17.44 13.735 4.018 4.859 6.415
Accrued Expenses 18.31 15.826 11.849 9.065 5.02
Notes Payable/Short Term Debt 0.456 0 0.454 0 0
Other Current Liabilities, Total 49.39 52.697 30.094 32.069 30.606
Total Liabilities 338.001 223.352 168.19 180.764 168.517
Total Long Term Debt 50.591 24.643 24.639 24.648 0
Other Liabilities, Total 201.814 116.451 97.136 110.123 126.476
Total Equity 10.783 131.507 174.75 -48.324 -48.045
Common Stock 0.125 0.092 0.091 0.07 0.041
Additional Paid-In Capital 875.181 745.829 723.482 411.255 341.284
Retained Earnings (Accumulated Deficit) -864.511 -614.354 -548.776 -459.649 -389.37
Other Equity, Total -0.012 -0.06 -0.047 0
Total Liabilities & Shareholders’ Equity 348.784 354.859 342.94 132.44 120.472
Total Common Shares Outstanding 125.222 91.8894 91.4592 70.1432 40.9367
Redeemable Preferred Stock
Total Receivables, Net 0 9.387 1.785
Accounts Receivable - Trade, Net 0 9.387 1.785
Long Term Debt 50.591 24.643 24.639 24.648
Current Port. of LT Debt/Capital Leases 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 214.394 251.238 116.081 194.764 247.513
Cash and Short Term Investments 169.912 229.52 106.544 181.341 233.003
Cash & Equivalents 169.912 229.52 94.841 163.03 205.398
Short Term Investments 0 0 11.703 18.311 27.605
Total Receivables, Net 16.857 7.559
Accounts Receivable - Trade, Net
Prepaid Expenses 9.1 8.819 9.537 13.423 14.51
Total Assets 367.699 406.387 270.194 348.784 311.868
Property/Plant/Equipment, Total - Net 131.671 134.309 133.22 133.969 43.231
Property/Plant/Equipment, Total - Gross 181.322 182.276 179.66 179.009 88.501
Accumulated Depreciation, Total -49.651 -47.967 -46.44 -45.04 -45.27
Long Term Investments 0 0
Other Long Term Assets, Total 21.634 20.84 20.893 20.051 21.124
Total Current Liabilities 79.225 77.898 63.818 85.596 81.819
Accounts Payable 8.958 12.922 12.297 17.44 10.449
Accrued Expenses 19.759 17.158 11.661 18.31 18.114
Notes Payable/Short Term Debt 0 0 0 0.456 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 50.508 47.818 39.86 49.39 53.256
Total Liabilities 382.822 383.773 318.065 338.001 244.283
Total Long Term Debt 101.135 100.742 51.234 50.591 50.857
Long Term Debt 101.135 100.742 51.234 50.591 50.857
Other Liabilities, Total 202.462 205.133 203.013 201.814 111.607
Total Equity -15.123 22.614 -47.871 10.783 67.585
Common Stock 0.129 0.128 0.127 0.125 0.124
Additional Paid-In Capital 921.735 911.62 887.685 875.181 863.294
Retained Earnings (Accumulated Deficit) -936.987 -889.133 -935.685 -864.511 -795.715
Other Equity, Total 0 -0.001 0.002 -0.012 -0.118
Total Liabilities & Shareholders’ Equity 367.699 406.387 270.194 348.784 311.868
Total Common Shares Outstanding 128.631 128.038 126.593 125.222 124.411
Total Inventory 18.525 5.34
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -250.157 -65.578 -89.127 -70.279 -98.942
Cash From Operating Activities -228.815 6.688 -93.61 -76.52 -62.854
Cash From Operating Activities 6.629 5.947 6.578 7.603 7.862
Non-Cash Items 33.103 24.789 12.136 10.783 16.427
Cash Interest Paid 4.926 2.446 2.453 0.221 0
Changes in Working Capital -18.39 41.53 -23.197 -24.627 11.799
Cash From Investing Activities 82.428 64.088 -158.891 -30.518 112.318
Capital Expenditures -9.821 -9.566 -0.591 -1.002 -1.937
Other Investing Cash Flow Items, Total 92.249 73.654 -158.3 -29.516 114.255
Cash From Financing Activities 129.602 1.178 303.424 86.231 0.268
Issuance (Retirement) of Stock, Net 103.903 2.126 283.524 61.656 0.268
Net Change in Cash -16.786 71.953 50.923 -20.807 49.732
Financing Cash Flow Items 0 19.9 -0.425
Issuance (Retirement) of Debt, Net 25.699 -0.948 25
Foreign Exchange Effects -0.001 -0.001
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -71.174 -250.157 -181.361 -121.359 -56.624
Cash From Operating Activities -76.584 -228.815 -175.922 -116.342 -66.445
Cash From Operating Activities 1.4 6.629 5.002 3.255 1.57
Non-Cash Items 12.527 33.103 23.324 14.302 5.607
Cash Interest Paid 1.737 4.926 3.282 1.836 0.558
Changes in Working Capital -19.337 -18.39 -22.887 -12.54 -16.998
Cash From Investing Activities 2.739 82.428 76.502 36.371 12.972
Capital Expenditures -4.068 -9.821 -6.36 -5.113 -2.95
Other Investing Cash Flow Items, Total 6.807 92.249 82.862 41.484 15.922
Cash From Financing Activities 5.656 129.602 125.005 26.978 26.848
Issuance (Retirement) of Stock, Net 5.656 103.903 102.585 1.279 1.149
Net Change in Cash -68.189 -16.786 25.583 -52.993 -26.625
Financing Cash Flow Items -3.279
Issuance (Retirement) of Debt, Net 0 25.699 25.699 25.699 25.699
Foreign Exchange Effects -0.001 -0.002

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Seres Therapeutics Inc Company profile

About Seres Therapeutics Inc

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis and SER-155 to treat enteric bacterial pathogens.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Seres Therapeutics Inc revenues increased from $33.2M to $144.9M. Net loss decreased 26% to $65.6M. Revenues reflect Collaboration revenue - related party increase from $11.9M to $143.9M. Lower net loss reflects Interest income increase from $946K to $2.9M (income), Interest expense remaining flat at $2.9M (expense).

Industry: Bio Therapeutic Drugs

200 Sidney St
CAMBRIDGE
MASSACHUSETTS 02139-4218
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,573.47 Price
+1.790% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

XRP/USD

0.64 Price
+2.520% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading